Bendamustine and Melphalan in Myeloma

Summary

Bendamustine and Melphalan in Myeloma is a clinical trial^[1].

Key Facts

• Bendamustine and Melphalan in Myeloma is in the country of Switzerland^[2].
• Bendamustine and Melphalan in Myeloma's instance of is recorded as clinical trial^[3].
• Bendamustine and Melphalan in Myeloma's start time is recorded as +2017-07-20T00:00:00Z^[4].
• Bendamustine and Melphalan in Myeloma's end time is recorded as +2020-10-31T00:00:00Z^[5].
• Bendamustine and Melphalan in Myeloma's main subject is recorded as multiple myeloma^[6].
• Bendamustine and Melphalan in Myeloma's number of participants is recorded as {'unit': '1', 'amount': '+120'}^[7].
• Bendamustine and Melphalan in Myeloma's title is recorded as A Randomized Phase II Trial Comparing Bendamustine and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients^[8].
• Bendamustine and Melphalan in Myeloma's short name is recorded as BEB-2^[9].
• Bendamustine and Melphalan in Myeloma's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• Bendamustine and Melphalan in Myeloma's ClinicalTrials.gov ID is recorded as NCT03187223^[11].
• Bendamustine and Melphalan in Myeloma's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+75'}^[12].
• Bendamustine and Melphalan in Myeloma's research intervention is recorded as melphalan^[13].
• Bendamustine and Melphalan in Myeloma's research intervention is recorded as bendamustine hydrochloride^[14].
• Bendamustine and Melphalan in Myeloma's clinical trial phase is recorded as phase II clinical trial^[15].
• Bendamustine and Melphalan in Myeloma's research site is recorded as University of Bern^[16].
• Bendamustine and Melphalan in Myeloma's study type is recorded as interventional study^[17].